EpCAM Antibody - #DF6311

Fig. 5: Therapeutic potentials of Pg-Fe-hMSC in both monocellular and multicellular humanized fibrotic models. a Schematic illustration and representative image of EpCAM immunostaining in primary human lung epithelial cells (hLECs). Scale bar, 50 μm. b Mitochondrial transfer rates from the indicated hMSC to the primary hLEC (n = 3 biologically independent cells). c Relative intracellular ROS levels (n = 3 biologically independent cells), d TGF-β expression levels (n = 4 biologically independent cells), and e Viability of BLM-treated hLEC after the indicated treatment using different engineered hMSCs (n = 3 biologically independent cells). f Schematic illustration showing the preparation of the 3D multicellular human fibrotic model. g Representative immunostaining images showing the expression of α-smooth muscle actin (α-SMA), vimentin, collagen-I, and Ki-67 in the healthy and fibrotic multicellular human spheroid models. Blue fluorescent signals indicate the cell nuclei and green signals indicate the biomarkers. Scale bar, 20 μm. h Mitochondrial transfer rates of different engineered hMSC in fibrotic human lung spheroids (n = 3 biologically independent experiments). i Relative intracellular ROS levels (n = 3 biologically independent experiments) and j TGF-β expression levels of fibrotic human lung spheroids after the indicated treatment using different engineered hMSCs (n = 4 biologically independent experiments). k Viability of fibrotic human lung spheroids after the indicated treatment using different engineered hMSCs (n = 3 biologically independent experiments). Data are presented as means ± SD. Statistical significance was analyzed using ordinary one-way ANOVA. ECs epithelial cells

Figure S4| Isolation and authentication of exosomes.(C) Exosomes were further verified by WB using CD63, CD9, CD81 and EpCAM antibodies.